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The endogenous neuropeptide nociceptin/orphanin FQ, translated from the prepronociceptin gene,
exerts a contraction-inhibitory effect on the rat uterus. As nocistatin has been reported to cause
functional antagonism of the pro-nociceptive effects of nociceptin, we set out to investigate its effects on
the pregnant rat uterus and to elucidate its signalling pathway. The expression of prepronociceptin
mRNA in the uterus and nocistatin levels in the uterus and the plasma were conﬁrmed by RT-PCR and
radioimmunoassay. The uterine levels of prepronociceptin mRNA and nocistatin were signiﬁcantly
increased by the last day of pregnancy, while the plasma nocistatin levels remained unchanged. In the
isolated organ bath studies nocistatin inhibited the prostaglandin- and the KCl-evoked contractions in
the uterus dose-dependently. This latter effect was decreased by preincubation with capsaicin.
Incubation with calcitonin gene-related peptide after capsaicin treatment caused an elevation in the
contraction-inhibitory effect of nocistatin. The effect of nocistatin was also decreased by the Ca2
+-dependent K+ channel inhibitor paxilline, against spontaneous uterine contractions. Nociceptin
potentiated the action of nocistatin. Naloxone decreased the effect of nocistatin administered either
alone or in combination with nociceptin. In Ca2+-poor environment, this effect of naloxone was
suspended. Enzyme immunoassay for the uterine intracellular cAMP levels partially conﬁrmed the
results of in vitro contractility studies. We conclude that nocistatin, generated locally in the uterus, exerts
an inhibitory effect, the mechanism being mediated in part by Ca2+-dependent K+ channels, the elevation
of cAMP levels and sensory neuropeptides.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
After the identiﬁcation of the endogenous ligand nociceptin
(N/OFQ) of the nociceptin receptor (NOP receptor), another neuro-
peptide originating from the same precursor protein prepronoci-
ceptin (PNOC) was isolated (Okuda-Ashitaka et al., 1998). It was
named nocistatin, with reference to its ﬁrst effects described in
the central nervous system, as a functional antagonist of N/OFQ
(Zeilhofer et al., 2000). It has been demonstrated that nocistatin
binds to a binding site that is distinct from the NOP receptor
(Okuda-Ashitaka and Ito, 2000; Johnson and Connor, 2007).
Nocistatin inhibits 5-hydroxytryptamine release via a Gi/o protein-
mediated pathway (Johnson and Connor, 2007; Fantin et al., 2007).
The mRNA for PNOC is widely expressed in the brain (Neal
et al., 1999; Martin et al., 1998) and in the spinal cord (Mollereaull rights reserved.
spár).et al., 1996). Nocistatin attenuates the allodynia and hyperalgesia
caused by the intrathecal administration of N/OFQ and PGE2
(Minami et al., 1994a, 1994b; Taiwo and Levine, 1988; Okuda-
Ashitaka et al., 1998). Both N/OFQ and nocistatin have impacts on
memory and learning (Hiramatsu and Inoue, 1999). Nocistatin
suppresses appetite (Olszewski et al., 2000) and induces gastric
mucosal protection (Zádori et al., 2008).
Endogenous opioid peptides are involved in the induction of
the GnRH surge (Foradori et al., 2007). N/OFQ is present in several
pathological conditions, such as the female ﬁbromyalgia syndrome
(Anderberg et al., 1998) and postpartum depression (Gu et al.,
2003), and it is a paracrine mediator of the FSH effects in the
regulation of spermatogenesis (Eto et al., 2012). A high expression
of N/OFQ in adenomyosis may be one of the casual factors of
dysmenorrhoea (Hou et al., 2011). N/OFQ regulates the LH surge
and ovarian function (Sinchak et al., 2006). The N/OFQ–NOP receptor
system modulates and coordinates reproductive behaviour and
physiology through actions in the limbic system and hypothalamus
(Sinchak et al., 2006).
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of uterine contractility, including oxytocin and tachykinin
promoting contractions (Popescu et al., 1985; Pennefather et al.,
2004; Moodley et al., 1999; Collins et al., 2002). Other neuropep-
tides, such as calcitonin gene-related peptide (CGRP), contribute to
relaxation of the uterus smooth muscle (Shew et al., 1991;
Pennefather et al., 1990; Klukovits et al., 2004). CGRP and tachyki-
nin are localised in the capsaicin-sensitive sensory nerve endings.
As labour and delivery are extremely painful, we decided to
evaluate the effects of PNOC-derived peptides which have a role
in pain modulation, in order to establish whether they additionally
inﬂuence uterine contractility. We earlier reported that the endo-
genous peptide N/OFQ inhibits uterine contraction in the pregnant
rat (Klukovits et al., 2010).
Our present aims were to detect the expression of PNOC mRNA
and nocistatin in the late-pregnant rat uterus and to clarify the
effects of nocistatin alone or in combination with N/OFQ in vitro.
We hypothesised that Ca2+-activated K+ channels (KCa1.1) and
outward K+ currents, the changes in intracellular cAMP levels, and
sensory neuropeptide CGRP may be involved in the uterine effects
of nocistatin. Additionally, we aimed to investigate the opiate-
receptor-independent peripheral actions of nocistatin.2. Materials and methods
2.1. Animals
The animals were treated in accordance with the European
Communities Council Directives (86/609/ECC) and the Hungarian
Act for the Protection of Animals in Research (XXVIII.tv.32.§). All
experiments involving animal subjects were carried out with the
approval of the Hungarian Ethical Committee for Animal Research
(registration number: IV./01758-2/2008) and under the control of
the ISO-9001:2008 Quality Management System.
Sexually mature female Sprague-Dawley rats (body mass: 160–
200 g, 50–60 days old) were mated in the early morning hours.
Copulation was conﬁrmed by the presence of a copulation plug or
spermatozoa in the vagina. The day of copulation was considered
to be the ﬁrst day of pregnancy. The animals were housed in
temperature (20–23 1C), humidity (40–60%) and light (12 h of light,
12 h of dark)-regulated rooms, with water and food intake
available ad libitum.
2.2. Real-time reverse transcription polymerase chain reaction
(RT-PCR) studies
On selected days of late pregnancy (days 18, 20 and 22), rats
were killed by CO2 inhalation, the uteri were excised and trimmed
of fat, the feto-placental units were removed and the endome-
trium was denuded. The tissue samples were frozen immediately
in liquid nitrogen, and then stored at −80 1C until analysis. The
frozen samples were ground with a Micro-Dismembrator S homo-
geniser (Sartorius, Germany), and the total RNA was isolated with
the TRIsure Kit according to the manufacturer's instructions. RNA
purity was controlled via the optical density at 260/280 nm with a
BioSpec Nano instruments (Shimadzu, Japan); all samples exhib-
ited an absorbance ratio in the range 1.6–2.0. RNA quality and
integrity were assessed by agarose gel electrophoresis. One micro-
gram of each sample of total RNA was used for reverse transcrip-
tion and ampliﬁcation (TaqMan RNA-to-CT 1-Step Kit and the Sensi
FAST Probe Hi-Rox One-Step Kit). The following primers were
used: assay ID Rn01637101_m1 for PNOC, Rn 00667869_m1 for
ß-actin and Rn 01775763_g1 for GAPDH as endogenous controls.
RT-PCR was performed by using the ABI StepOne Real-Time cycler.
The ﬂuorescence intensities of the probes were plotted againstPCR cycle numbers. The ampliﬁcation cycle displaying the ﬁrst
signiﬁcant ﬂuorescence signal increase was deﬁned as the thresh-
old cycle (CT).
There is an ongoing debate about the applicability of beta-actin
as a gene reference in the pregnant rat uterus, with no reassuring
conclusion as yet (Kelly et al., 2003). Thus we have repeated our
PCR studies also with GAPDH as a gene reference. We did not ﬁnd
differences in the change of PNOC mRNA when GAPDH was used
as compared with beta-actin.
2.3. Radioimmunoassay (RIA) for nocistatin in the rat uterus
and plasma
In RIA studies, blood and uterine samples from non-pregnant
and 15-, 18-, 20- and 22-day pregnant rats were used.
Blood was collected in K3-EDTA containing vacutainers (OMKER,
Hungary) and Aprotinin (0.6 TIU/ml) was added immediately as a
protease inhibitor. Plasma was separated by centrifugation at
3000 rpm for 10 min and samples were kept frozen at −80 1C until
direct analysis by radioimmunoassay (RIA).
1000 μl aliquots of plasma samples were mixed with equal
volume of 1% v/v triﬂuoroacetic acid (TFA I.), centrifuged at 1600g
for 20 min at 4 1C. The acidiﬁed samples were loaded onto C18
Sep-Pack cartridges (ABL&E JASCO Hungary Ltd.), washed twice
with TFA I., and then eluted with 60% acetonitrile in 0.1% TFA.
Samples were freeze dried by centrifugation (SAVANT, Instru-
ments, Inc., Farmingdale, NY, USA). The reconstituted eluate was
subjected to RIA using commercially available 125I-Nocistatin RIA
kit with minimum sensitivity of 10 pg/ml. Data were evaluated by
RIA-Mat 280 (Byk-Sangtec, Dietzenbach, Germany).
Extraction of nocistatin was carried out by a validated method
adapted from Eun-Mee et al. (1999) and Hofbauer et al. (2000).
Uterus samples were treated with 1 M acetic acid (250 mg/ml),
placed in a 95 1C water bath for 5 min then cooled in ice-cold
water bath for 10 min and homogenised by an Ultra Turrax T25
Janke&Kunkel homogeniser (IKA Labortechnik, Staufen, Germany)
at 20,000 rpm for 10 s, followed by an ultrasound homogenisation
(Labsonic 2000, B.Braun, AG, Melsungen Germany) for 10 s.
Samples were replaced in the 95 1C water bath for 5 min then
cooled in ice-cold water bath, and centrifuged at 4 1C for 10 min
at 12,000g in an Eppendorf centrifuge (A. Hettich, Tuttlingen,
Germany). Aliquots of 1.0 ml from the supernatants were treated
as described for plasma samples.
During the validation of the extraction procedure stability of
nocistatin, reproducibility, recovery and linearity of recovery in the
10–500 pg/100 mg tissue concentration range were determined.
Recovery was 8970.87%, and all the other parameters were in the
normal range.
2.4. In vitro contractility studies
2.4.1. Uterus preparation
On day 22 of pregnancy (at term), the rats were killed by CO2
inhalation, and the uteri were removed and prepared for the
in vitro contractility assay as reported previously (Klukovits et al.,
2010). Brieﬂy, the isolated uterine horns were immediately placed
in an organ bath (de Jongh solution; containing in mM: 137 NaCl,
3 KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4 Na2HPO4, 6 glucose; pH 7.4)
perfused with a mixture of 95% oxygen and 5% carbon dioxide
(carbogen) and trimmed of fat, and the feto-placental units were
removed. The temperature was maintained at 37 1C. Four rings
0.5 cm long were sliced from the middle part of each horn,
including implantation sites, and tested in parallel; they were
mounted vertically in the above-mentioned organ bath containing
10 ml of de Jongh solution. After mounting, the initial tension was
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solution change every 15 min.Fig. 1. Levels of expression of PNOCmRNA in the rat uterus on days 18, 20 and 22 of
pregnancy. As term was approached, the PNOC mRNA level increased; there was a
signiﬁcant increase in the level of PNOCmRNA in uterus samples obtained from rats
on day 22 (i.e. at term) as compared with that on day 20 of pregnancy (n¼3);
nnnPo0.001, ns: non-signiﬁcant. Signiﬁcances are expressed relative to the
previous column. The endogenous control is β-actin.2.4.2. Nocistatin studies
In the isolated uterine rings, rhythmic contractions were
elicited with 25 mM KCl or with 10 nM oxytocin or with 1 μM
PGF2α. Without washing out the contractile agents, the effects of
nocistatin on the uterine contractions were tested in the concentra-
tion range 10−12–10−6 M, in a noncumulative manner (as regards its
peptide characteristic). After each concentration of nocistatin, the
rings were washed 3 times, allowed to recover for 5 min, and then
contracted again with the above-mentioned agents. Following the
oxytocin- and PGF2α-induced contractions, the contraction-
inhibitory effect of nocistatin was also investigated in the presence
of N/OFQ (10−8 M).
Following the KCl-induced contractions, the contraction-inhibitory
effect of nocistatin was investigated in the presence of N/OFQ
(10−8 M) and/or naloxone (10−8 M). The most potent inhibitory effect
of nocistatin was found in the KCl-induced contractions; this agent
was therefore used to investigate the possible mechanism of nocis-
tatin in further studies. As naloxone induces an increase in inward Ca2
+ currents (Kai et al., 2002), we conducted a series of experiments in
a low Ca2+ environment in order to investigate whether the inhibitory
effect of naloxone on the nocistatin-induced uterus relaxation is
mediated by the opening of inward rectifying Ca2+ channels. Thus
the joint effect of nocistatin and naloxone was studied in a modiﬁed
de Jongh buffer, containing half the Ca2+ concentration (0.5 mM
CaCl2) of the standard de Jongh buffer (Hajagos-Tóth et al., 2009).
In order to investigate the participation of the outward rectifying
K+ channels in mediating the effects of nocistatin, tests were
performed in the presence of the KCa1.1 channel-selective blocker
paxilline (510−6 M), against spontaneous uterine contractions.
The possible involvement of the sensory neuropeptide CGRP in
the actions of nocistatin was also tested on uterine tissue. In this set
of experiments, capsaicin (1 μM dissolved in physiological saline
containing 6% Tween 80 and 8% ethanol; for 10 min) was used to
deplete CGRP from the uterine sensory nerve endings (Holzer, 1991).
After thorough washing out, the tissues were incubated with CGRP
(0.1 μM; 20 min) (Sams-Nielsen et al., 2001) and washed again, and
the effects of nocistatin were tested as above. These experiments
were performed in a de Jongh solution supplemented with protease
inhibitors such as phenylmethanesulfonyl ﬂuoride (1 μM), captopril
(0.1 mM), dithiothreitol (0.5 mM), soy bean trypsin inhibitor (1 mM)
and aprotinin (36,000 kIU/l).
The tension of the myometrial rings was measured with a
strain gauge transducer (SG-02, Experimetria Ltd., Budapest,
Hungary), and recorded and analysed with the SPEL Advanced
ISOSYS Data Acquisition System (Experimetria Ltd., Budapest,
Hungary). The areas under the curves of 4-min periods were
evaluated; the effects of nocistatin, N/OFQ and naloxone were
expressed as percentages of KCl/oxytocin/PGF2α-induced or spon-
taneous contractions. The dose–response curves were ﬁtted and
the geometrical mean of log EC50 values and maximum
contraction-inhibitory values were calculated with the Prism
4.0 computer programme (GraphPad Inc., San Diego, CA, USA).
2.5. Measurement of uterine cAMP accumulation
As cAMP elevation plays a major role in the relaxation of
uterine smooth muscle, we set out to investigate its possible
involvement in the nocistatin signalling. Uterine tissue samples
were incubated in de Jongh solution at 37 1C, perfused with
carbogen. cAMP accumulation was determined in the presence
of the nonspeciﬁc phosphodiesterase inhibitor 3-isobutyl-
1-methylxanthine (IBMX; 10−3 M; 10 min), nocistatin (10−8 M;10 min) alone or in combination with N/OFQ (10−8 M) or naloxone
(10−8 M), and the adenylyl cyclase activator forskolin (10−5 M;
10 min). The samples were then immediately frozen in liquid
nitrogen and stored until the extraction of cAMP. Frozen tissue
samples were ground, weighed, homogenised in 10 volumes of
ice-cold 5% trichloroacetic acid and centrifuged at 1000g for
10 min. The supernatants were extracted with 3 volumes of
water-saturated diethyl ether. After drying, the extracts were
stored at -80 1C until the cAMP assay. Uterine cAMP accumulation
was measured with a commercial competitive cAMP enzyme
immunoassay (EIA) kit and tissue cAMP levels were expressed in
pmol/mg tissue. All samples (n¼4 in each group) were measured
in duplicate in the EIA.
2.6. Materials
N/OFQ and nocistatin were purchased from PolyPeptide Labora-
tories France SAS, Strasbourg, France. PGF2α, naloxone, forskolin,
IBMX, cAMP Enzyme Immunoassay Kit, paxilline, capsaicin, soy bean
trypsin inhibitor, dithiothreitol, phenylmethanesulfonyl ﬂuoride and
captopril were from Sigma-Aldrich Ltd., Budapest, Hungary. The
TRIsure Kit and the Sensi FAST Probe Hi-Rox One-Step Kit were from
Bioline Ltd., Budapest, Hungary. TaqMan RNA-to-CT 1-Step Kit,
β-actin and GAPDH primers were obtained from Life Technologies,
Budapest, Hungary. The 125I-Nocistatin RIA kit was from Phoenix
Pharmaceuticals, Inc., purchased by Izinta Ltd., Budapest, Hungary.
Aprotinin (Gordoxs) and oxytocin were purchased from Richter
Gedeon Ltd., Budapest, Hungary.
2.7. Statistical analysis
Statistical analyses were carried out by ANOVA Newman–Keuls
multiple comparison test with the Prism 4.0 computer programme
(GraphPad Inc., San Diego, CA, USA). This test makes pairwise
comparisons of group means. The alpha level of Newman–Keuls
test is 0.05.3. Results
3.1. Measurement of PNOC mRNA in the uterus
The myometrial PNOC mRNA levels increased signiﬁcantly as
term was approached. The PCR study showed that the levels of
PNOC mRNA/β-actin mRNA and PNOC mRNA/GAPDH mRNA were
the lowest on pregnancy day 18. The relative expression of PNOC
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increased signiﬁcantly by day 22, the day of delivery; Po0.001
(Fig. 1, the endogenous control was β-actin; we observed the same
results with GAPDH, data not shown).
3.2. Measurement of nocistatin in the uterus and the plasma
The myometrial nocistatin levels increased signiﬁcantly as term
was approached. The RIA experiments revealed that the levels of
nocistatin were relatively low on pregnancy days 15, 18 and 20
(P40.05), then elevated signiﬁcantly by day 22, the day of
delivery; Po0.05 as compared with day 20 (Table 1). The
nocistatin levels on day 22 did not differ from the non-pregnant
samples. The plasma levels of nocistatin did not change as term was
approached (days 15, 18, 20 and 22; P40.05 in all comparisons).Table 1
Tissue and plasma nocistatin levels in non-pregnant, 15, 18, 20 and 22 day pregnant
rats (n¼6).
Tissue pg/100 mg uterine
tissue7S.E.M
pg/ml plasma7
S.E.M
Non-pregnant 47.0774.66 12.0771.53
15 day pregnant 17.4974.41 a 14.1171.63 ns
18 day pregnant 17.1573.03 ns 11.5271.62 ns
20 day pregnant 13.9571.82 ns 12.1971.57 ns
22 day pregnant 42.1176.27 a 17.5972.12 ns
a Po0.05, ns: nonsigniﬁcant. Signiﬁcances are expressed relative to the value
of the previous tested day.
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Fig. 2. Representative online recordings of the inhibitory effects of nocistatin on pregna
(A) or with 1 μM prostaglandin F2 alpha (PGF2α; B) or with 25 mM KCl (C). Nocistatin in
alter the oxytocin-evoked contractions.3.3. In vitro contractility studies
3.3.1. Investigation of the contraction-inhibitory effects of nocistatin
The contraction-inhibitory effect of nocistatin was investigated
in three different agonist-induced contractions (Fig. 2). The
oxytocin-, PGF2α- or KCl-stimulated contractions did not decrease
signiﬁcantly through the experiment. Oxytocin was able to con-
tract the uterine smooth muscle, but in the presence of oxytocin,
nocistatin alone or in the presence of N/OFQ (10−8 M) did not
signiﬁcantly reduce the contractions (data not shown). In the
case of PGF2α-induced contractions, nocistatin and N/OFQ dis-
played slight inhibitory effects (Fig. 3). There was no signiﬁcant
difference between the log EC50 values. Nocistatin alone decreased
the KCl-induced contractions concentration-dependently. Co-
administration of N/OFQ (10−8 M) with nocistatin, however, sig-
niﬁcantly increased the maximum contraction-inhibitory effect of
nocistatin; Po0.05 (Fig. 4A). There was no signiﬁcant difference
between the log EC50 values (Table 2). The most potent inhibitory
effect of nocistatin was found in the KCl-induced contractions; this
agent was therefore used to investigate the possible mechanism of
nocistatin in further studies.3.3.2. Investigation of the contraction-inhibitory effects of nocistatin
and naloxone in a standard and a Ca2+-poor environment
In standard de Jongh solution, the maximum inhibitory effect of
nocistatin was decreased by naloxone (10−8 M); Po0.001. There was
no signiﬁcant difference between the log EC50 values (Table 3).
Naloxone also decreased the maximum contraction-inhibitory effectevaluated periods (4 min) 
evaluated periods (4 min) 
evaluated periods (4 min) 
l 
ytocin nocistatin(10-7M)
nocistatin(10-7M)
nocistatin(10-7M)
2
nt uterine contractions in vitro. The contractions were elicited with 10 nM oxytocin
hibited the prostaglandin F2 alpha and KCl-induced contractions, though it did not
Fig. 3. Inhibitory effects of nocistatin and nociceptin (N/OFQ) on pregnant uterine
contractions in vitro. The contractions were elicited with 1 μM prostaglandin
F2 alpha. The concentration-dependent inhibitory effect of nocistatin (●) was
increased by N/OFQ (Δ); n¼6.
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no signiﬁcant difference between the log EC50 values (Table 2).
In the Ca2+-poor environment, the concentration–response
curves of nocistatin alone and of nocistatin in combination with
naloxone were both shifted to the left as compared with the curves
in standard de Jongh solution. The log EC50 values of nocistatin
alone and of nocistatin with naloxone were signiﬁcantly lower in
the Ca2+-poor environment than in standard de Jongh solution
(Po0.05). At the same time, naloxone did not decrease the
inhibitory effect of nocistatin in the Ca2+-poor environment as it
did in the standard buffer. The maximum contraction-inhibitory
effect of nocistatin alone did not differ from that of nocistatin in
combination with naloxone in the Ca2+-poor buffer (Fig. 4B and
Table 3).Fig. 4. Effects of nocistatin and naloxone on pregnant uterine contractions in a
standard and a low Ca2+ environment in vitro. The contractions were elicited with
25 mM KCl in 22-day-pregnant rat uterine rings. The concentration-dependent
inhibitory effect of nocistatin (●) was signiﬁcantly attenuated by naloxone (■);
n¼10. When nocistatin, N/OFQ and naloxone were present, the joint effect of the3.3.3. Investigation of the role of KCa1.1 channels in mediating
the effects of nocistatin
The effects of nocistatin on the spontaneous contractions of the
term-pregnant rat uterus were also tested in the presence of the
selective KCa1.1 channel inhibitor paxilline (510−6 M), (Fig. 5). In
the presence of paxilline, the maximum contraction-inhibitory
effect of nocistatin (Emax: 33.0472.83%) was decreased signiﬁ-
cantly (Emax: 11.1573.61%; Po0.001), while there was no
signiﬁcant difference between the log EC50 values (log EC50:
−8.2970.45 and −9.4770.93).three drugs (◊) was decreased as compared with the dual effect of nocistatin and
N/OFQ (Δ); n¼6 (A). The concentration-dependent inhibitory effect of nocistatin (○)
was not altered by naloxone (□) in the Ca2+-poor buffer, whereas it was inhibited in
the standard Ca2+-containing buffer (● nocistatin; ■ naloxone); n¼6 (B).3.3.4. Investigation of the role of CGRP in mediating the effects
of nocistatin
Since the exact site of action of nocistatin is still unclear, we
tested whether it might act by modulating neuropeptide release
from capsaicin-sensitive sensory nerve endings in the pregnant rat
uterus. Neuropeptide depletion from the capsaicin-sensitive pri-
mary afferents was induced with capsaicin (Fig. 6). The maximum
contraction-inhibitory effect of nocistatin was decreased signiﬁ-
cantly (Po0.01) after preincubation with capsaicin (1 mM;
Table 4). The solvent of capsaicin (control) did not change the
effect of nocistatin (P40.05).
When the neuropeptide depletion was followed by the addition
of CGRP (0.1 mM), the maximum contraction-inhibitory effect of
nocistatin was signiﬁcantly higher than after incubation withcapsaicin (Po0.01). The addition of CGRP restored the inhibitory
effect of nocistatin as compared with the control (P40.05).
3.4. Measurement of uterine cAMP accumulation
We also investigated whether cAMP accumulation plays a role
in the contraction-inhibitory effect of nocistatin (Fig. 7). Nocistatin
evoked a signiﬁcant increase (Po0.001) in the uterine cAMP
level (15.1270.40 pmol/mg tissue) as compared with the basic
activity (12.8270.17 pmol/mg tissue). Co-administration of N/OFQ
with nocistatin caused a further elevation in the cAMP level
Table 2
log EC50 and maximum contraction-inhibitory values of nocistatin alone and in the
presence of nociceptin (N/OFQ) on prostaglandin F2α (PGF2α) or KCl-stimulated
contractions; and of nocistatin with N/OFQ+naloxone on KCl-stimulated contrac-
tions in the 22-day-pregnant rat uterus in vitro (n¼8).
Substance log EC50
(7S.E.M.)
Emax
(%7S.E.M.)
Nocistatin (on PGF2α-evoked contraction) −10.9270.22 25.9073.16
Nocistatin+N/OFQ −11.0770.21 ns 38.7174.26 a
Nocistatin (on KCl-evoked contraction) −8.0270.18 56.1074.82
Nocistatin+N/OFQ −7.7570.27 ns 65.7879.42 a
Nocistatin+N/OFQ+naloxone −8.1770.27 b 40.3372.73 c
a Po0.05, ns: nonsigniﬁcant; signiﬁcances are expressed relative to
nocistatin alone.
b Nonsigniﬁcant; signiﬁcances are expressed relative to nocistatin in the
presence of N/OFQ.
c Po0.05.
Table 3
log EC50 and maximum contraction-inhibitory effects of nocistatin alone and in the
presence of naloxone on KCl-stimulated uterine contractions in the 22-day-
pregnant rat in vitro, either in standard Ca2+-containing or in Ca2+-poor de Jongh
solutions (n¼6).
Substance log EC50 (7 S.E.M.) Emax (%7S.E.M.)
Nocistatin (1 mM Ca2+) −8.0270.18 56.1074.82
Nocistatin+naloxone (1 mM Ca2+) −8.0170.47 ns 24.7873.08 a
Nocistatin (0.5 mM Ca2+) −10.4270.23 b 47.2174.27
Nocistatin+naloxone (0.5 mM Ca2+) −10.6670.24 ns; b 47.8274.85 ns
a Po0.001, ns: nonsigniﬁcant. The signiﬁcances of the joint effect of nocistatin
+naloxone are expressed relative to nocistatin alone in the same Ca2+-containing
de Jongh solution.
b Po0.05; signiﬁcances are expressed relative to the same substance in a
different Ca2+-containing de Jongh solution.
Fig. 5. Effects of paxilline on the contraction-inhibitory effect of nocistatin in vitro.
The spontaneous contractions were recorded in 22-day-pregnant uterine rings
from the rat. The concentration-dependent inhibitory effect of nocistatin (●) was
decreased by paxilline (▲); n¼8.
Fig. 6. The role of calcitonin gene-related peptide (CGRP) on the contraction-
inhibitory effect of nocistatin in vitro. The contractions were elicited with 25 mM
KCl in 22-day-pregnant rat uterine rings. The concentration-dependent inhibitory
effect of nocistatin (●; control) was reduced signiﬁcantly after preincubation with
capsaicin (□; 1 mM). Addition of CGRP (0.1 mM) after preincubation with capsaicin
caused a signiﬁcant elevation of the concentration–response curve of nocistatin (Δ);
n¼6.
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was co-administered with nocistatin, a signiﬁcant decrease was
detected in the cAMP level (13.3570.52 pmol/mg tissue) as
compared with the effect of nocistatin alone (Po0.05).4. Discussion
Many studies have been reported on the central effects of
nocistatin, but none on the peripheral effects of nocistatin. We
earlier described the uterus-relaxant effect of N/OFQ, a peptide
derived from the same precursor as nocistatin (Klukovits et al.,
2010). Nocistatin displays opposite effects to those of N/OFQ in the
central nervous system. Our present aims were to determine the
peripheral effects of nocistatin on the rat uterus in vitro, and to
elucidate its signalling mechanism.
PNOC mRNA is expressed predominantly in the central nervous
system (the brain and spinal cord). A previous study also con-
ﬁrmed its presence in human peripheral blood mononuclear cells
(Williams et al., 2008), and it has been detected in the rat ovary
(Mollereau et al., 1996; Leo et al., 2001). However, the expressions
of PNOC mRNA and nocistatin have not been investigated to date
in the uterus. We found that the common precursor for N/OFQ and
nocistatin, the PNOCmRNA, is expressed locally in the pregnant rat
uterus, indicating that N/OFQ and nocistatin are synthesised
locally. This ﬁnding justiﬁes a local regulatory role for these pro-
nociceptive peptides, in the term pregnant rat uterus.
In addition, we detected the presence of nocistatin in the
pregnant and non-pregnant rat uterus. Both the expressions
of PNOC mRNA and of nocistatin were high on the last day of
pregnancy, as compared with earlier days. Furthermore, we found
that nocistatin in the pregnant rat uterus at term is about 10 times
more abundant than N/OFQ, so it seems that PNOC mRNA is
translated mainly to nocistatin, rather than N/OFQ. The plasma
level of nocistatin did not change at the end of pregnancy, which
further conﬁrms the local origin of nocistatin in the uterus.
After conﬁrming that N/OFQ is effective in inhibiting uterine
contractions (Klukovits et al., 2010), we investigated whether
nocistatin inﬂuences the uterine smooth muscle in vitro. Although
nocistatin possesses a contraction-inhibitory effect on KCl- and PGF2α-
evoked contractions, its action against PGF2α was weak. N/OFQ was
able to potentiate the inhibitory effect of nocistatin in both cases.
Nocistatin does not counteract the effects of N/OFQ on the myome-
trium contractility, as was presumed in previous studies relating to
their actions in the central nervous system. However, nocistatin was
ineffective on oxytocin-induced contractions. This phenomenon will
Table 4
log EC50 and maximum contraction-inhibitory effects of nocistatin after preincubation with capsaicin (1 mM), with the solvent of capsaicin (control) and with capsaicin
(1 mM) and CGRP (0.1 mM) (n¼6).
Substance log EC50 (7S.E.M.) Max. inhibition at 10−7 M nocistatin (%7S.E.M.)
Nocistatin control −9.0470.43 48.7277.18
Nocistatin preincubated with capsaicin Not converged 6.1474.79 a
Nocistatin preincubated with capsaicin and CGRP −9.0670.46 35.0577.38 a
a Po0.01. Signiﬁcances after preincubation with capsaicin are expressed relative to nocistatin alone, and signiﬁcances after preincubation with capsaicin and CGRP &QJ;
are expressed relative to preincubation with capsaicin alone.
Fig. 7. Effects of nocistatin on intracellular cAMP levels in the pregnant rat uterus.
Nocistatin caused a signiﬁcant elevation in cAMP level as compared with the
control (black column); nnnPo0.001. The presence of N/OFQ increased (nnPo0.01),
while naloxone decreased (nPo0.05) the nocistatin-induced intracellular cAMP
accumulation.
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of nocistatin on the pregnant rat myometrium.
Naloxone inhibits the contraction-inhibitory effect of nocistatin
against KCl-induced contractions. Nocistatin does not bind to any
of the classical opioid receptors, or to the NOP receptor (Johnson
and Connor, 2007; Fantin et al., 2007), thus this inhibition is not
likely to be mediated by opioid receptors. It was demonstrated
that naloxone induces an increase in inward Ca2+ currents (Kai
et al., 2002). These ﬁndings led us to investigate whether the
inhibitory effect of naloxone on nocistatin-induced uterus relaxa-
tion is mediated by the opening of inward rectifying Ca2+
channels. To test our hypothesis, we used a Ca2+-poor environ-
ment, where naloxone did not inhibit the effect of nocistatin. We
presume that, in a low extracellular Ca2+ concentration, naloxone
is probably unable to promote a Ca2+ inﬂux, and hence it cannot
overcome the relaxation induced by nocistatin. The leftward shift
in the concentration–response curves are likely to be due to the
weaker tissue contractility, caused by the lower Ca2+ content.
When N/OFQ was present, naloxone was able to decrease the
common contraction-inhibitory effect of nocistatin and N/OFQ.
However, we found earlier that naloxone increases the effect of
N/OFQ (Klukovits et al., 2010). The effect seen here is probably the
consequence of the more pronounced inhibitory effect of nocista-
tin as compared with that of N/OFQ.
After the description of the contraction-inhibitory effect of
nocistatin in the in vitro contractility studies, our further aim
was to investigate some of the potential nocistatin signalling
pathways.
In the uterus, the plentiful KCa1.1 channels play an important
role in decreasing depolarisation, thereby relaxing the uterine
smooth muscle. These channels are activated by a cAMP-
dependent phosphorylation pathway (Chanrachakul et al., 2004).We set out to investigate the role of K+ currents in the intracellular
signalling of nocistatin. Paxilline, a selective inhibitor of the KCa1.1
channels, inhibited the contraction-inhibitory effect of nocistatin,
as evidence that the Ca2+-dependent K+ channels play a role in the
intracellular signalling of nocistatin.
As regards the higher contractility during delivery, the
elevation of nocistatin levels in the myometrium at term appears
rather contradictory, since nocistatin has uterus relaxing effect.
Nevertheless, it was also reported to inhibit hyperalgesia and
allodynia, thus it has a regulatory role in pain signalling, which
may explain its functional importance during labour. Additionally,
inﬂammatory mediators play a role in the initiation of labour, yet
some of them (e.g. CGRP) exhibit utero-relaxant activity among
their various effects.
Opioid-like nociceptive peptides have been reported to release
neurotransmitters such as CGRP or substance P (SP) from capsaicin-
sensitive primary sensory neurons (Peiser et al., 2000; Helyes et al.,
1997). These neuropeptides are synthesised in the dorsal root
ganglia (DRG) cells, stored in vesicles and released by exocytosis
(Lundberg, 1996) in response to electrical (Markowitz et al., 1987;
Buzzi et al., 1991) or chemical stimulation (Kilo et al., 1997). CGRP
has been reported to inhibit smooth muscle contractility in a variety
of tissues, including the pregnant rat uterus (Pennefather et al.,
1990). Other studies have reported that the binding of 125I-CGRP to
rat uterine membranes was increased during pregnancy and
decreased during parturition (Yallampalli et al., 1999). It is known
that denervation takes place in the myometrium during pregnancy,
but this process mainly affects adrenergic nerves and does not
involve the sensory units, including CGRP-containing nerves
(Klukovits et al., 2004).
The potential involvement of CGRP in the actions of nocistatin
on the pregnant rat uterus was therefore also tested. While
capsaicin causes the depletion of CGRP from sensory nerve
terminals (Holzer, 1991), other studies have furnished evidence
of a CGRP reload into the sensory nerve terminals after depletion
by capsaicin (Sams-Nielsen et al., 2001). We investigated the effect
of nocistatin either on capsaicin-induced CGRP-depleted uterus
samples or on CGRP-reloaded uterus samples. Capsaicin blocked
the contraction-inhibitory effect of nocistatin, which was restored
after the tissue samples were incubated with CGRP. Consequently,
we assume that CGRP is an important factor in the contraction-
inhibitory effect of nocistatin.
To support the hypothesis of the cross-talk between nocistatin
and CGRP, a special population of opioid receptors in DRG neurons
was reported, where low doses of opioids can provoke hyperalge-
sia, due to the activation of excitatory opioid receptors on the
afferent nerve terminals (Crain and Shen, 2000). There is
biochemical and pharmacological evidence that this phenomenon
involves an increased release of excitatory neuropeptides, including
CGRP and SP, in the spinal cord (Xu et al., 2003; Wiesenfeld-Hallin
et al., 1991; Crain and Shen, 1990). We assume that nocistatin,
similarly to opioid peptides and N/OFQ, may promote the release of
neuropeptides from sensory nerves (Moran et al., 2000). This
mechanism may explain the ineffectiveness of nocistatin against
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agonist adrenomedullin also failed to block oxytocin-evoked con-
tractions, whereas it was effective against spontaneous and
bradykinin-induced contractions (Yanagita et al., 2000).
For further investigation of the mechanism by which nocistatin
inhibits uterine contractions, the effect of nocistatin on uterine
cAMP accumulation was measured. We detected moderate eleva-
tion of cAMP levels in the presence of nocistatin, similarly as in the
case of N/OFQ. In the presence of N/OFQ with nocistatin, a further
cAMP level elevation was found, which can be explained by
the mutual cAMP-accumulating effects of N/OFQ and nocistatin-
induced CGRP liberation (Klukovits et al., 2010; Dong et al., 2005).
In correlation with the in vitro contractility studies, naloxone
decreased the cAMP levels elevated by nocistatin, which suggests
that naloxone interferes with nocistatin at the level of G-protein
activation, too.
Due to the CGRP-releasing effect of nocistatin, the relaxant
mechanism seems to be an indirect pathway. On the other hand,
the opening of potassium channels and inducing inward potas-
sium current may also play a role in the regulation of the relaxing
effect of nocistatin, and can be considered as direct effect on
uterine smooth muscle. Thus nocistatin might have both direct
and indirect dilatory effect on myometrium.5. Conclusions
These results provide evidence that nocistatin alone and also in
combination with N/OFQ, generated locally in the uterus, exert an
inhibitory effect in the rat uterus, this mechanism being mediated
mainly by KCa1.1 channels and consequent hyperpolarization, and
by release of the sensory neuropeptide CGRP. Naloxone inhibits
the contraction-inhibitory effect of nocistatin by activating inward
rectifying Ca2+ channels and by decreasing the cAMP-accumulating
effect of nocistatin. The elevated cAMP levels moderately contribute
to the uterus-relaxing effect of nocistatin. This complex signalling
pathway may provide an opportunity for the development of novel
treatments for the inhibition of uterine contractions and hence
prevent preterm birth. The ﬁndings of this in vitro study need to be
evaluated under in vivo conditions, and further experiments on
human tissue are necessary in order to allow conclusions on the
relevance of the present ﬁndings as concerns human disease.Acknowledgement
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